Path : Home > Industry > Dechra Completes Acquisition of Gallant Pet, Expanding into Veterinary Regenerative Medicine

Dechra Completes Acquisition of Gallant Pet, Expanding into Veterinary Regenerative Medicine


Nov 22, 2026

Dechra has completed its acquisition of Gallant Pet Inc., a US-based animal health biotechnology company developing regenerative medicine therapies for companion animals. The transaction was finalized on November 17, 2026, following the acquisition agreement announced on November 9.

The deal expands Dechra's veterinary healthcare portfolio into regenerative medicine, adding Gallant's pipeline of ready-to-use mesenchymal stromal cell (MSC) therapies. The financial terms of the acquisition were not disclosed.

Gallant focuses on developing cell-based treatments designed to address chronic and complex conditions in dogs and cats. Its research pipeline covers feline chronic gingivostomatitis, osteoarthritis in cats and dogs, feline chronic kidney disease, and canine atopic dermatitis.

MSC therapies are being investigated for their potential to regulate immune responses, reduce inflammation and support tissue repair. Gallant's treatments are still investigational and have not received FDA approval for general commercial use. Different candidates are at different stages of development, including clinical studies.

According to Dechra, the acquisition combines its veterinary specialty care expertise, international reach and established relationships with veterinary professionals with Gallant's scientific capabilities in regenerative medicine. The company expects the first innovation from Gallant's development pipeline as early as 2027.

For the animal health industry, the acquisition reflects growing corporate interest in advanced veterinary treatments beyond conventional pharmaceuticals. It also brings a specialist biotechnology developer into the portfolio of an established international veterinary healthcare company.

The next important steps will be the continued development of Gallant's clinical pipeline, regulatory progress and the eventual commercialization of its therapies. For veterinary pharmaceutical companies, biotechnology developers and animal health investors, the transaction is another development to watch in the emerging veterinary regenerative medicine sector.

 


  • Previous: JBT Marel Unites Wenger and Extru-Tech Under One Brand for Pet Food Processing
  • Next: Thailand’s AAI Reports Higher Q3 Profit as Pet Food Margins Improve
  • Industry News

    Partner Links

    Go to Top

    HOME - About PetsGlobal.com - Pet Industry Links - Update my company - Contact PetsGlobal.com

    © 2001-2026 PetsGlobal.com All right reserved